Related Experiment Videos
Type 1 phosphatase, a negative regulator of cardiac function.
Andrew N Carr1, Albrecht G Schmidt, Yoichi Suzuki
1Department of Pharmacology and Cell Biophysics, University of Cincinnati, Cincinnati, Ohio 45267, USA.
Molecular and Cellular Biology
|May 25, 2002
Summary
Increased protein phosphatase 1 (PP1) activity worsens heart failure. Inhibiting PP1 may offer a new therapeutic strategy for patients with heart failure.
Area of Science:
- Cardiology
- Molecular Biology
- Biochemistry
Background:
- Elevated protein phosphatase 1 (PP1) activity is noted in end-stage human heart failure.
- The precise role of PP1 in cardiac function remains unclear.
Purpose of the Study:
- To investigate the functional significance of increased PP1 activity in the heart.
- To explore PP1 as a potential therapeutic target for heart failure.
Main Methods:
- Generated murine models with PP1 catalytic subunit overexpression.
- Created models with PP1-specific inhibitor ablation.
- Examined beta-adrenergic responses in failing human myocytes.
Main Results:
- PP1 overexpression led to depressed cardiac function, dilated cardiomyopathy, and reduced survival in mice.
- Inhibitor ablation resulted in moderate PP1 activity increase and impaired beta-adrenergic responses.
- Increased PP1 activity in human heart failure may stem from inhibitor inactivation.
- Restoring inhibitor activity rescued beta-adrenergic responsiveness in failing human myocytes.
Conclusions:
- Protein phosphatase 1 (PP1) plays a critical role in regulating cardiac function.
- PP1 activity is a significant contributor to heart failure pathophysiology.
- Inhibiting PP1 activity presents a promising therapeutic avenue for heart failure treatment.